Summary
This prediction is currently active. The BUY prediction by robertinio for Evotec SE is nearly unchanged. This prediction currently runs until 20.08.25. The prediction end date can be changed by robertinio at any time. robertinio has 100% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Evotec SE | -0.61% |
| iShares Core DAX® | 4.097% |
| iShares Nasdaq 100 | 5.110% |
| iShares Nikkei 225® | 5.333% |
| iShares S&P 500 | 3.487% |
According to robertinio what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Cons
Risky Investment
Revenue decline/stagnation expected
Comments by robertinio for this prediction
In the thread Evotec AG diskutieren
Buy Evotec SE